Innovative
Therapeutics for
Better Health
Because Life
Shouldn't Have to
Wait for Migraines
Our Lead Product Candidate
STS101
Dihydroergotamine (DHE) Nasal Powder
Learn More
Clinical Trials
SUMMIT™ Trial
Currently Recruiting
Learn More
Press Releases
Sep 20, 2022
Satsuma Pharmaceuticals Announces Positive Results from the Ongoing STS101 ASCEND Phase 3 Open-label, Long-term Safety Trial
Read More
Sep 06, 2022
Satsuma Pharmaceuticals to Present at the H.C. Wainwright 24th Annual Global Investment Conference
Read More
